HRP20221381T1 - C-manozidni spojevi korisni za liječenje infekcija urinarnog trakta - Google Patents

C-manozidni spojevi korisni za liječenje infekcija urinarnog trakta Download PDF

Info

Publication number
HRP20221381T1
HRP20221381T1 HRP20221381TT HRP20221381T HRP20221381T1 HR P20221381 T1 HRP20221381 T1 HR P20221381T1 HR P20221381T T HRP20221381T T HR P20221381TT HR P20221381 T HRP20221381 T HR P20221381T HR P20221381 T1 HRP20221381 T1 HR P20221381T1
Authority
HR
Croatia
Prior art keywords
methyl
compound
pharmaceutically acceptable
acceptable salt
hydroxy
Prior art date
Application number
HRP20221381TT
Other languages
English (en)
Inventor
Michael Joseph Bishop
Vincent J. Colandrea
Yuehu LI
Eugene L. Stewart
Iulia STRAMBEANU
Katherine Louisa Widdowson
James Walter Janetka
Laurel Kathryn MCGRANE
Original Assignee
Glaxosmithkline Intellectual Property Development Limited
Fimbrion Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Intellectual Property Development Limited, Fimbrion Therapeutics, Inc. filed Critical Glaxosmithkline Intellectual Property Development Limited
Publication of HRP20221381T1 publication Critical patent/HRP20221381T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04Carbocyclic radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Claims (15)

1. Spoj formule I, ili njegova farmaceutski prihvatljiva sol, [image] u kojem Rl je CH3, CF3 ili Cl; R2 je F, Cl, OR' ili H; R3, R4 i R5 su neovisno H, F, Cl, Br, C3-6cikloalkil, OR', -N(C1-6alkil)2, C2-6 alkenil, C2-6 alkinil ili C1-6 alkil izborno supstituiran sa do sedam atoma fluora, do jednog hidroksi, do jednog -N(C1-6 alkil)2, i do jednog -OC1-6alkila; pod uvjetom da svi R3, R4 i R5 nisu istovremeno vodik. R5 je H ili F; R' je neovisno H ili C1-6 alkil izborno supstituiran sa do sedam atoma fluora.
2. Spoj ili njegova farmaceutski prihvatljiva sol prema zahtjevu 1, naznačen time što Rl je CH3 ili CF3.
3. Spoj ili njegova farmaceutski prihvatljiva sol prema zahtjevu 1 ili 2, naznačen time što R1 je CH3.
4. Spoj ili njegova farmaceutski prihvatljiva sol prema zahtjevu 1, naznačen time što Rl je CH3 ili CF3; R2 je H; R3 je F; R4 je CH3, Cl, Br, vinil, CF3, F ili H; R5 je F ili H; i R6 je H.
5. Spoj prema zahtjevu 4 koji je odabran između: (2R,3S,4S,5S,6R)-2-((R)-(3',5'-difluoro-3,4'-dimetil-[1,1'-bifenil]-4-il)(hidroksi)metil)-6-(hidroksimetil)tetrahidro-2H-piran-3,4,5-triol; (2R,3S,4S,5S,6R)-2-((R)-(4'-kloro-3',5'-difluoro-3-metil-[1,1'-bifenil]-4-il) (hidroksi)metil)-6-(hidroksimetil)tetrahidro-2H-piran-3,4,5-triol; (2R,3S,4S,5S,6R)-2-((R)-(4'-bromo-3',5'-difluoro-3-metil-[1,1'-bifenil]-4-il) (hidroksi)metil)-6-(hidroksimetil)tetrahidro-2H-piran-3,4,5-triol; (2R,3S,4S,5S,6R)-2-((R)-(3',5'-difluoro-3-metil-4'-vinil-[l,l'-bifenil]-4-il) (hidroksi)metil)-6-(hidroksimetil)tetrahidro-2H-piran-3,4,5-triol; (2R,3S,4S,5S,6R)-2-((R)-(3'-fluoro-3-metil-4'-(trifluorometil)-[1,1'-bifenil]-4-il) (hidroksi)metil)-6-(hidroksimetil)tetrahidro-2H-piran-3,4,5-triol; (2R,3S,4S,5S,6R)-2-((R)-(3'-fluoro-3-metil-5'-(trifluorometil)-[1,1'-bifenil]-4-il) (hidroksi)metil)-6-(hidroksimetil)tetrahidro-2H-piran-3,4,5-triol; (2R,3S,4S,5S,6R)-2-((R)-hidroksi(3',4',5'-trifluoro-3-metil-[1,1'-bifenil]-4-il) metil)-6-(hidroksimetil)tetrahidro-2H-piran-3,4,5-triol; (2R,3S,4S,5S,6R)-2-((R)-(3',5'-difluoro-3-(trifluorometil)-[1,1'-bifenil]-4-il)(hidroksi)metil)-6-(hidroksimetil)tetrahidro-2H-piran-3,4,5-triol; i (2R,3S,4S,5S,6R)-2-((R)-(3',5'-difluoro-3-metil-[1,1'-bifenil]-4-il)(hidroksi)metil) -6-(hidroksimetil)tetrahidro-2H-piran-3,4,5-triol.
6. Spoj prema bilo kojem od zahtjeva 1 do 5, naznačen time što je spoj [image]
7. Spoj ili njegova farmaceutski prihvatljiva sol naveden u bilo kojem od zahtjeva 1-6 za uporabu kao lijek.
8. Spoj ili njegova farmaceutski prihvatljiva sol kako je navedeno u bilo kojem od zahtjeva 1-6 za uporabu u prevenciji ili liječenju bolesti ili stanja poboljšanog inhibicijom funkcije ili aktivnosti FimH.
9. Spoj ili njegova farmaceutski prihvatljiva sol kako je navedeno u bilo kojem od zahtjeva 1-6 za uporabu u prevenciji ili liječenju bakterijske infekcije, Crohnove bolesti (CD), i upalne bolesti crijeva (IBD).
10. Spoj ili njegova farmaceutski prihvatljiva sol kako je navedeno u bilo kojem od zahtjeva 1-6 za uporabu u prevenciji ili liječenju infekcije urinarnog trakta (UTI).
11. Spoj ili njegova farmaceutski prihvatljiva sol kako je navedeno u zahtjevu 10, naznačen time što je navedena infekcija urinarnog trakta rekurentna ili kronična.
12. Spoj ili njegova farmaceutski prihvatljiva sol kako je navedeno u zahtjevu 9, naznačen time što navedena bakterijska je infekcija bakterijska infekcija otporna na antibiotike.
13. Farmaceutski pripravak koji sadrži spoj ili njegovu farmaceutski prihvatljivu sol kako je navedeno u bilo kojem od zahtjeva 1-6 zajedno s farmaceutski prihvatljivim nosačem.
14. Farmaceutski pripravak koji sadrži spoj ili njegovu farmaceutski prihvatljivu sol kako je navedeno u bilo kojem od zahtjeva 1-6 formuliran za oralnu (PO) primjenu, posebno naznačen time što je navedeni pripravak tableta ili kapsula.
15. Spoj ili njegova farmaceutski prihvatljiva sol kako je navedeno u bilo kojem od zahtjeva 1-6; i drugo terapeutsko sredstvo.
HRP20221381TT 2018-07-10 2019-07-08 C-manozidni spojevi korisni za liječenje infekcija urinarnog trakta HRP20221381T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862695993P 2018-07-10 2018-07-10
US201862755588P 2018-11-05 2018-11-05
EP19769220.5A EP3820856B9 (en) 2018-07-10 2019-07-08 C-mannoside compopunds useful for the treatment of urinary tract infections
PCT/IB2019/055806 WO2020012336A1 (en) 2018-07-10 2019-07-08 C-mannoside compounds useful for the treatment of urinary tract infections

Publications (1)

Publication Number Publication Date
HRP20221381T1 true HRP20221381T1 (hr) 2023-01-06

Family

ID=67957191

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20221381TT HRP20221381T1 (hr) 2018-07-10 2019-07-08 C-manozidni spojevi korisni za liječenje infekcija urinarnog trakta

Country Status (24)

Country Link
US (3) US11111262B2 (hr)
EP (1) EP3820856B9 (hr)
JP (2) JP7309862B2 (hr)
KR (1) KR20210031682A (hr)
CN (1) CN112334455B (hr)
AU (1) AU2019301946B2 (hr)
BR (1) BR112021000370A2 (hr)
CA (1) CA3105940A1 (hr)
CL (1) CL2021000033A1 (hr)
DK (1) DK3820856T3 (hr)
ES (1) ES2928634T3 (hr)
HR (1) HRP20221381T1 (hr)
HU (1) HUE060140T2 (hr)
IL (1) IL279993B2 (hr)
LT (1) LT3820856T (hr)
MX (1) MX2021000340A (hr)
PH (1) PH12020551905A1 (hr)
PL (1) PL3820856T3 (hr)
PT (1) PT3820856T (hr)
RS (1) RS63712B1 (hr)
SG (1) SG11202011066XA (hr)
TW (1) TWI821328B (hr)
UY (1) UY38293A (hr)
WO (1) WO2020012336A1 (hr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3105940A1 (en) * 2018-07-10 2020-01-16 Glaxosmithkline Intellectual Property Development Limited C-mannoside compounds useful for the treatment of urinary tract infections
WO2020191091A1 (en) 2019-03-19 2020-09-24 Boehringer Ingelheim Animal Health USA Inc. Anthelmintic aza-benzothiophene and aza-benzofuran compounds
CN113461753B (zh) 2020-03-31 2023-05-23 郑计岳 2-炔基甘露糖衍生物及其应用
WO2021242581A1 (en) 2020-05-29 2021-12-02 Boehringer Ingelheim Animal Health USA Inc. Anthelmintic heterocyclic compounds
US11999742B2 (en) 2021-11-01 2024-06-04 Boehringer Ingelheim Vetmedica Gmbh Substituted pyrrolo[1,2-b]pyridazines as anthelmintics

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5122602A (en) 1989-02-13 1992-06-16 Miles Inc. Chromogenic merocyanine enzyme substrates
US6420127B1 (en) 1994-11-18 2002-07-16 Washington University Compounds and pharmaceutical compositions for the treatment and prophylaxis of bacterial infections
DK0730601T3 (da) 1993-11-18 2005-06-06 Univ Washington Forbindelser og farmaceutiske præparater til behandling af profylakse af bakterieinfektioner
EP1192038B1 (en) 1999-06-28 2003-11-05 Lear Corporation Method of forming a blow-molded plastic part having a living hinge
WO2001010386A2 (en) 1999-08-11 2001-02-15 Washington University Anti-bacterial compounds directed against pilus biogenesis, adhesion and activity; co-crystals of pilus subunits and methods of use thereof
EP1303256B1 (en) 2000-06-09 2009-01-07 Baylor College of Medicine The combination of antimicrobial agents and bacterial interference to coat medical devices
AU2003274127A1 (en) 2003-10-08 2005-04-21 Innovaprotean, S.L. Compounds for the treatment of diseases associated with the formation of amyloid fibrils
EP1755619A2 (en) 2004-03-23 2007-02-28 VIB vzw Anti-adhesive compounds to prevent and treat bacterial infections
SE528382C2 (sv) 2004-10-05 2006-10-31 Probi Ab Probiotiska lactobacillusstammar för förbättrad vaginal hälsa
FR2876798A1 (fr) 2004-10-14 2006-04-21 Univ Clermont Auvergne Diagnostic et traitement de la maladie de crohn
WO2011050323A1 (en) 2009-10-22 2011-04-28 The Washington University Compounds and methods for treating bacterial infections
AU2010333017B2 (en) 2009-12-14 2016-06-16 University Of Basel Mannose derivatives as antagonists of bacterial adhesion
ES2732311T3 (es) 2011-02-07 2019-11-21 Univ Washington Compuestos de manósidos y procedimientos de uso de los mismos
WO2012164074A1 (en) 2011-06-03 2012-12-06 University Of Basel Mannose phosphate derivatives as antagonists of bacterial adhesion
US20130261077A1 (en) 2012-03-07 2013-10-03 Vertex Pharmaceuticals Incorporated Mannose derivatives for treating bacterial infections
EP2690105A1 (en) 2012-07-24 2014-01-29 Centre National De La Recherche Scientifique Mannose derivatives, a process for preparing the same and their uses as a drug
US20140107049A1 (en) 2012-10-04 2014-04-17 Vertex Pharmaceuticals Incorporated Mannose derivatives for treating bacterial infections
PL2935302T3 (pl) 2012-12-18 2018-12-31 Vertex Pharmaceuticals Incorporated Pochodne mannozy do leczenia infekcji bakteryjnych
CA2905019C (en) 2013-03-12 2021-07-06 Vertex Pharmaceuticals Incorporated Mannose derivatives for treating bacterial infections
WO2014194270A1 (en) 2013-05-30 2014-12-04 Washington University Compounds and methods for treating bacterial infections
JP6961572B2 (ja) 2015-08-05 2021-11-05 アンテローム 付着性大腸菌と関連する病状の処置に有用なマンノース誘導体
JP2019508504A (ja) * 2016-03-11 2019-03-28 フィンブリオン セラピューティックス, インコーポレイテッドFimbrion Therapeutics, Inc. 疾病の処置に有用なc−グリコシド化合物
CA3018345A1 (en) 2016-03-23 2017-09-28 Fimbrion Therapeutics, Inc. Mannose-derived antagonists of fimh useful for treating disease
AU2018351471A1 (en) 2017-10-16 2020-05-07 Enterome New tools for assessing FimH blockers therapeutic efficiency
CA3105940A1 (en) * 2018-07-10 2020-01-16 Glaxosmithkline Intellectual Property Development Limited C-mannoside compounds useful for the treatment of urinary tract infections

Also Published As

Publication number Publication date
RS63712B1 (sr) 2022-11-30
DK3820856T3 (da) 2022-10-24
AU2019301946B2 (en) 2022-03-31
US11697665B2 (en) 2023-07-11
IL279993B1 (en) 2023-09-01
JP7309862B2 (ja) 2023-07-18
EP3820856B9 (en) 2023-07-12
JP2022511594A (ja) 2022-02-01
JP7483820B2 (ja) 2024-05-15
US20230287028A1 (en) 2023-09-14
TWI821328B (zh) 2023-11-11
CN112334455A (zh) 2021-02-05
SG11202011066XA (en) 2021-01-28
UY38293A (es) 2020-05-29
WO2020012336A1 (en) 2020-01-16
HUE060140T2 (hu) 2023-02-28
PT3820856T (pt) 2022-10-17
PL3820856T3 (pl) 2022-12-19
BR112021000370A2 (pt) 2021-04-06
CL2021000033A1 (es) 2021-07-30
PH12020551905A1 (en) 2021-06-21
ES2928634T3 (es) 2022-11-21
CN112334455B (zh) 2022-07-01
TW202019893A (zh) 2020-06-01
JP2022191325A (ja) 2022-12-27
MX2021000340A (es) 2021-03-25
IL279993A (en) 2021-03-01
AU2019301946A1 (en) 2020-11-26
EP3820856A1 (en) 2021-05-19
EP3820856B1 (en) 2022-08-31
US11111262B2 (en) 2021-09-07
US20210395287A1 (en) 2021-12-23
CA3105940A1 (en) 2020-01-16
KR20210031682A (ko) 2021-03-22
IL279993B2 (en) 2024-01-01
LT3820856T (lt) 2022-11-10
US20210017212A1 (en) 2021-01-21

Similar Documents

Publication Publication Date Title
HRP20221381T1 (hr) C-manozidni spojevi korisni za liječenje infekcija urinarnog trakta
HRP20161103T1 (hr) Kemijski spojevi
HRP20211762T1 (hr) Derivati benzoksaborola za liječenje bakterijskih infekcija
KR20180080189A (ko) 이상 염증 반응과 연관된 질환을 치료하기 위한 방법 및 조성물
HRP20171425T1 (hr) Derivati oksazolidin-2-on-pirimidina
HRP20171512T1 (hr) Derivati betulina
RU2018114480A (ru) Соли и твердые формы монобактамного антибиотика
RU2017109139A (ru) Таблетки, содержащие большую дозу рукапариба
FR2903107B1 (fr) Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique
RU2015133450A (ru) Соединения имидазопиридина и их применение
HRP20110869T1 (hr) Derivati pleuromutilina za liječenje bolesti posredovanih mikrobima
RS54258B1 (en) SRC / ABL INHIBITOR FORMULATIONS
HRP20151438T1 (hr) Sastavi stabilnih tiakumicina
UA109421C2 (uk) Фармацевтична композиція, яка містить ліганди сигма-рецептора
UY29085A1 (es) Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes
EA201291410A1 (ru) Фармацевтические композиции, содержащие 4-амино-5-фтор-3-[6-(4-метилпиперазин-1-ил)-1h-бензимидазол-2-ил]-1h-хинолин-2-она лактат моногидрат
JP2014517001A5 (hr)
HRP20171649T1 (hr) 4-supstituirani spojevi 3-fenilsulfanilmetilbiciklo[3.1.0]heksana kao antagonisti mglur 2/3
JP2019508504A5 (hr)
RU2018117499A (ru) Производные 6-[5-амино-6-(2-этоксиэтокси)-имидазо[4,5-b]пиридин-3-ил]никотинонитрила и их применение в качестве irak ингибиторов
JP5882296B2 (ja) 創傷の予防及び治療のための組成物及び方法
HRP20221230T1 (hr) Farmaceutske kombinacije koje sadrže inhibitor histon deacetilaze i inhibitor bcl-2 i postupci za njihovu uporabu
RU2019112148A (ru) Фармацевтическая композиция и способ лечения неалкогольной жировой болезни печени
NZ743987A (en) C-glucoside derivative containing fused phenyl ring or pharmaceutically acceptable salt thereof, process for preparing same, and pharmaceutical composition comprising same
HRP20240155T1 (hr) Spojevi i pripravci za induciranje hondrogeneze